CVRx, Inc. (CVRX) News
Filter CVRX News Items
CVRX News Results
|Loading, please wait...|
Latest CVRX News From Around the Web
Below are the latest news stories about CVRx Inc that investors may wish to consider to help them evaluate CVRX as an investment opportunity.
While the long-term outlook may predict a return to bullish conditions, for now investors have to contend with increased uncertainty and volatility. What they need is a sign, some signal to indicate stocks that are going to get through the current market environment. Insider trades are a common favorite among the signals available to investors, and for good reason. Corporate insiders – really, just company officers, positioned at the upper levels of management or the Boards, with an ‘inside’ view of everything behind the company and the stock – don’t trade lightly.
Fourth Quarter 2021 Revenue of $3.7 million, a 75% Increase Over Prior Year Fourth Quarter 2021 Revenue of $3.7 million, a 75% Increase Over Prior Year
CVRx press release (CVRX): Q4 GAAP EPS of -$0.52 misses by $0.07.Revenue of $3.7M (+76.2% Y/Y) misses by $0.07M.
MINNEAPOLIS, Feb. 01, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter and full year 2021 financial and operating results after market close on Tuesday, February 15, 2022. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same
MINNEAPOLIS, Jan. 10, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary unaudited fourth quarter and full year 2021 revenue results, and provided a 2022 business outlook. Fourth Quarter 2021 Total revenue for the fourth quarter of 2021 is expected to be in the range of approximately $3.6
No summary available.
MINNEAPOLIS, Dec. 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (CVRx), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022. The Company is scheduled to present at 3:45 pm Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Companys website at ir.cvrx.com . A replay of the webcast will be archived on the website for approximately 90 days. About CVRx, Inc. CVRx is focused on the development and commercialization of Barostim, the first ...
Axonics (NASDAQ:AXNX) and CVRx (NASDAQ:CVRX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Analyst Recommendations This is a breakdown of current ratings and recommmendations for Axonics and CVRx, as reported by 
CVRx, Inc. (NASDAQ:CVRX) Director Mudit K. Jain bought 875 shares of the firms stock in a transaction that occurred on Thursday, November 18th. The shares were acquired at an average cost of $14.63 per share, for a total transaction of $12,801.25. The transaction was disclosed in a document filed with the SEC, which is available